Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Control Of BioEquivalence With Xenical (COBEX): A Phase I, Randomised, Active-control Study to Evaluate EMP22 Pharmacodynamics and EMP16 Pharmacokinetics Versus Xenical in Healthy Volunteers

Next Previous
Trial Profile

Control Of BioEquivalence With Xenical (COBEX): A Phase I, Randomised, Active-control Study to Evaluate EMP22 Pharmacodynamics and EMP16 Pharmacokinetics Versus Xenical in Healthy Volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acarbose/orlistat (Primary) ; Orlistat
  • Indications Obesity
  • Focus Pharmacokinetics
  • Sponsors Empros Pharma

Most Recent Events

  • 01 Apr 2025 Results assessing comparative analysis of the pharmacokinetics and pharmacodynamics of 2 controlled release formulations of acarbose and orlistat (MR-OA) combination and conventional orlistat product, Xenical (Conv-O) by measuring fecal fat excretion, published in the Clinical Pharmacology in Drug Development.
  • 02 Oct 2023 Status changed from not yet recruiting to recruiting.
  • 31 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top